摘要
目的评价沐舒坦、盐酸川芎嗪注射液对老年社区获得性肺炎(CAP)疗效和安全性。方法将老年社区获得性肺炎106例随机分为治疗组和对照组,每组53例。治疗组沐舒坦、盐酸川芎嗪注射液辅助治疗,对照组常规治疗,比较两组患者的治疗结局、发热、咳嗽、咳痰、气喘、胸闷恢复时间、重症患者的病死率及住院时间的差异,检测治疗组患者的不良反应。结果治疗组重症患者的病死率明显低于对照组(P<0.01);治疗组患者的发热、咳嗽、咳痰、气喘、胸闷恢复时间均短于对照组(P<0.01);两组患者的住院时间明显短于对照组(P<0.01)。治疗组所有患者均未发现明显不良反应。结论沐舒坦、盐酸川芎嗪注射液辅助治疗老年社区获得性肺炎疗效可靠,安全性好,值得推广。
Objective To evaluate the efficacy and safety of treatment with combination ofAmbroxol Hydrochloride and Ligustrazine Hydrochloride Injection for the elderly patients with Community acquired pneumonia（CAP）.Methods 106 cases of Elderly patients with CAP were randomly divided into control group and treatment group,each group 53 cases.The control group received routine therapy while the treatment group received adjunctive treatment with combination ofAmbroxol Hydrochloride and Ligustrazine Hydrochloride Injection.Treatment outcome,recovery time of Symptoms,mortality in critically ill patients and length of Hospital Stay were compared between the two groups and adverse reactions of treatment group were observed.Results The mortality in critically ill patients of treatment group was significantly lower than that of contrast group（P0.01）.The recovery time of Symptoms such as Fever,cough,expectoration,wheezing,chest tightness and the length of Hospital Stay were significantly shorter than those of contrast group（P0.01）.There was no significant adverse effects in treatment group.Conclusion Treatment with combination of Ambroxol Hydrochloride and Ligustrazine Hydrochloride Injection is effective and safe for the elderly patients with Community acquired pneumonia（CAP）.
出处
《中国医药指南》
2012年第9期24-25,共2页
Guide of China Medicine
关键词
沐舒坦
盐酸川芎嗪氯化钠注射液
老年社区获得性肺炎
治疗
Mucosolvan
Ligustrazine Hydrochloride and Sodium Chloride Injection
Community acquired pneumonia（CAP）
Treatment
